Skip to main content
All lobbying filings

EDWARDS LIFESCIENCES, LLC

EDWARDS LIFESCIENCES, LLC filed a Q3 report for EDWARDS LIFESCIENCES LLC on October 20, 2025.

Lobbying for EDWARDS LIFESCIENCES LLC

All filings by EDWARDS LIFESCIENCES, LLC · Everything EDWARDS LIFESCIENCES LLC has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Expenses
$280,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Taxation/Internal Revenue Code

Corporate Tax Reform Proposals

Trade (domestic/foreign)

Tariffs Japan Reimbursement of Medical Devices

Health Issues

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials

Medicare/Medicaid

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

 Bills named in this filing 2
  • H.R. 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S. 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem